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nucleate due to devitalization of the cells and thus inac-
tivation of the calcium pump.5 It has been demonstrated
that calcification does initiate in the cells6; however, this
would appear to be at odds with the fact that cusps stored
in glutaraldehyde for more than 1 year no longer calci-
fy,7 and valves treated with high concentrations of glu-
taraldehyde have diminished calcification.8 In both
cases, cells and their remnants are present in the colla-
gen/elastin matrix. For this reason, work has also
focused on decellularization of the porcine collagen/
elastin matrix.9 Membrane-bound phospholipids have
also been associated with calcification nucleation due to
alkaline phosphatase hydrolysis.10 Ethanol has been
used to remove phospholipids and mitigate calcification,
yet phospholipids have also been removed with chloro-
form-methanol yielding less than optimum antimineral-
ization efficacy on the basis of rat subcutaneous experi-
ments.11 This would indicate that phospholipid removal
alone is not sufficient to mitigate calcification. Lipid
extraction can also be performed through tissue process-
ing with detergent compounds such as sodium dodecyl
sulfate. Subcutaneous rat studies indicate this approach
to be efficacious, although circulatory models have
demonstrated mixed results.12 The primary concern with
lipid extraction methods is the potential for collagen
matrix degradation if the processes are too aggressive.10
Free aldehyde within the tissue matrix has been thought
to be an initiator for calcification as well. This is sup-
ported by studies that demonstrate that aldehyde-bind-
ing agents such as alpha-amino oleic acid (AOA;
Biomedical Design, Marietta, Ga), L-glutamic acid, and
aminodiphosphonate prevent cusp calcification.13-16 Yet,
post treatment with the amino acid lysine does not pre-
vent cuspal calcification.17 The foregoing often conflict-
ing information serves to underscore the complexity of
the bioprosthetic valve calcification process and empha-
sizes the multiplicity of pathways by which calcification
can initiate. 
Because theories for bioprosthetic valve calcification
exist without definitive proof, the approaches used by
industry and researchers to seek solutions to this clini-
cal failure modality have been based on observed phe-
nomena. Processes have been developed and then
assessed to ensure reproducibility, desired tissue bio-
mechanics, desired surface chemistry, matrix stability,
and resistance to calcification through a battery of in
Be not the first by whom the new are tried,
Nor yet the last to lay the old aside.
—Alexander Pope, An Essay on Criticism
This quotation befits the surgical community as it col-lectively ponders how much technology to embrace
with respect to current and future bioprosthetic heart
valve designs. It can be argued that current regulatory
guidance document governing development of these
prostheses adequately safeguards against the potential
for catastrophic structural failures decoupled from bio-
logic influence, for example, stent fracture and tissue
dehiscence. The current state of preclinical assessment
for the “biologic degradation” of the valvular compo-
nents is not as predictive given the inherent variability
and complexity of the human biologic system into which
these devices are implanted. Granted, preclinical evalu-
ation in a variety of animal models is used to access a
valve design’s functionality and resistance to calcifica-
tion; however, it is often difficult to extrapolate such data
to the long-term human experience.
The intent of this editorial is to provide a broad
overview of what is thought to be the mechanisms of
calcification in bioprosthetic heart valves, list the cur-
rent fixation processes in the literature, and examine
how prostheses are evaluated for their antimineraliza-
tion efficacy. Above all, it is my hope that this editorial
will spur thought and challenge industrial, clinical, and
academic scientists to seek better techniques for the
evaluation of new tissue fixation processes.
Glutaraldehyde-fixed heart valves were first implanted
in 1967 after it was determined that glutaraldehyde sta-
bilized collagenous biomaterials.1,2 Although valves
thus treated were nonthrombogenic, they failed because
of calcific degeneration.3,4 Much has been written yet
little has been proven as to the mechanisms for this cal-
cification. It has been postulated that calcium phosphate
crystals containing sodium, magnesium, and carbonate
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vitro and in vivo tests. A variety of treatments have
been used clinically as well as experimentally. They
may be broken down into two broad categories: modi-
fications to glutaraldehyde processed tissue and non-
glutaraldehyde processes. The modifications to glu-
taraldehyde processed tissue include but are not limited
to treatments with detergents such as sodium dodecyl
sulfate and Tween-80 to remove phospholipids,12
ethanol preincubation to remove phospholipids,11 cova-
lently bound AOA, L-glutamic acid and aminodiphos-
phonate to bind free aldehydes,13-17 and detoxification
processes using urazole18 and homocysteic acid.19
Nonglutaraldehyde processes include but are not limit-
ed to epoxy compounds,20 dye-mediated photo-oxida-
tive reactions including PhotoFix21 (Sulzer Carbo-
medics, Austin, Tex) and carbodiimide compounds
including Ultifix (Biomedical Design).22
Some of these processes have clinical experience and
some do not. Clinical data are difficult to access rela-
tive to bioprosthetic valvular calcification, because
valves are not usually explanted unless demonstrable
valvular performance issues are present that cause
stenosis and/or incompetence. This is further con-
founded by the fact that one must also layer into the
analysis the host of patient factors that can bias inter-
pretations. The resulting analysis in general yields a
statement as to whether a valve was calcified or not.
Although this is valuable, it does not provide insight as
to the mechanism for the presence of or lack of calcifi-
cation. This may change, however. A recent publication
by Melina and associates23 demonstrated a real time in
vivo technique using electron beam computed tomog-
raphy to assess calcification in both aortic leaflets and
aortic wall with stentless xenografts and homografts.
This represents a first hope at getting the mechanistic
question answered noninvasively in human beings.
The root cause for our inability to determine the
mechanisms for bioprosthetic heart valve calcification
lies in the limitations of the models we use in the pur-
suit of this knowledge. Current preclinical in vivo tech-
niques for the assessment of bioprosthetic heart valve
calcification revolve around analysis of explants from
two animal models—the rat subcutaneous model and
the juvenile sheep. Values for calcification from the rat
subcutaneous model favorably trend with those from
the juvenile sheep.10,11 Thus, despite being static and
lacking blood contact, the rat subcutaneous model can
be used to screen processes before committing to the
expense of large animal studies. In addition to the stan-
dard 8-week implant duration reported by most investi-
gators using the subcutaneous rat model, spatial studies
should be undertaken with freshly processed and aged
shelf life valves to ensure any effect noted is in fact pre-
sent as opposed to simply offset in time.24 The sheep
model uses an orthotopic implant. As such, it is blood
contacting and integrates the unknown role of cyclic
mechanical stress into the determination of calcifica-
tion resistance. The downfall is that, because of the
time and expense associated with conducting such
studies, the use of statistically valid sample sizes is pro-
hibitive, rendering results difficult to interpret should
biologic variation occur. In general, the predictive
capacity of both models suffers from differences
between their lipoprotein profile and accelerated calci-
um metabolism as compared with human beings.
Neither incorporates the cardiovascular disease effects
and neither accurately reflects the coagulation path-
ways of human beings. The latter is important, as at
present there is no validated thromboembolism model
for the assessment of modified and/or new tissue fixa-
tion/stabilization technology incorporated into heart
valve designs. 
Given the limitations of preclinical in vivo biopros-
thetic valvular calcification assessment techniques,
researchers have long sought to develop in vitro meth-
ods. Calcium-rich solutions have been applied to bio-
prosthetic valves placed into dynamic operation in vitro
at a variety of frequencies.25-27 The limitation of this
technique revolves not around the ability to produce
calcification but to correlate the histologic and ultra-
structural manifestation of this calcification to that seen
in the animal models and in human beings. In this issue
of the Journal, Pettenazzo and associates describe their
in vitro test system and results. They were able to pro-
duce extrinsic nodular and laminar calcific deposits.
The intrinsic calcification noted on the basis of trans-
mission electron microscopic analysis was associated
at the microstructural level with collagen and elastin
fibrils. Most notably, however, they saw minimal calci-
fication associated with xenograft cells and cellular
debris. This is at odds with evidence reported from bio-
logic models and human explants.5,6 This is not to say
that such modeling is not valuable. Rather, it under-
scores the need for additional validations with this
technology. Greater sample size is necessary to ensure
the model’s sensitivity. Spatial studies must be com-
pleted to determine apatite initiation sites and their
growth characteristics, and processes with data from
animal models should be assessed in the present in
vitro model to determine whether a correlation exists.
The ultimate answer is that no single model or analy-
sis will contain the necessary predictive power to deter-
mine a bioprosthetic heart valve’s potential to calcify.
The key to the assessment of bioprosthetic valvular cal-
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cification lies in the usage of multiple models and the
understanding of their limitations. As we collectively
move the state of the art forward for the assessment of
calcification efficacy with bioprostheses, the patients
receiving these devices will ultimately benefit because
new technology will have lower risk with greater hope
of demonstrating clinical efficacy. Once achieved and
borne out by the scrutiny of science, we can then say,
on this one issue, that Alexander Pope’s first comment
should not apply. 
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